Ardelyx, Inc. (ARDX)

Market Cap	1.17B
Revenue (ttm)	251.85M
Net Income (ttm)	-72.58M
Shares Out	236.85M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,334,520
Open	4.750
Previous Close	4.790
Day's Range	4.680 - 4.960
52-Week Range	4.060 - 10.130
Beta	0.91
Analysts	Buy
Price Target	11.75 (+138.82%)
Earnings Date	Oct 31, 2024

About ARDX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of el...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2014
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDX
• Website: https://www.ardelyx.com

Financial Performance

In 2023, Ardelyx's revenue was $124.46 million, an increase of 138.61% compared to the previous year's $52.16 million. Losses were -$66.07 million, -1.70% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $11.75, which is an increase of 138.82% from the latest price.

Price Target

$11.75

(138.82% upside)

Analyst Consensus: Buy